<DOC>
	<DOCNO>NCT00691470</DOCNO>
	<brief_summary>The purpose research study test experimental drug ATI-5923 v Coumadin . The study intend demonstrate ATI-5923 superior Coumadin keep INR value desire therapeutic range . Patients require chronic anticoagulation one follow condition eligible study : atrial fibrillation atrial flutter , prosthetic heart valve , venous thromboembolic disease , history myocardial infarction cardiomyopathy enrol .</brief_summary>
	<brief_title>Comparison ATI-5923 , Novel Vitamin K Antagonist , With Warfarin Patients Requiring Chronic Anticoagulation</brief_title>
	<detailed_description>The primary study objective evaluate whether ATI-5923 superior adjust dose warfarin quality anticoagulation measure interpolated INR time therapeutic range . This Phase II/III multi-center , randomize , stratify , double blind , parallel group , active control study compare ATI-5923 Coumadin patient require chronic , oral anticoagulation . Up 600 patient successfully complete screen assessment meet eligibility criterion enrol study receive study drug treatment 6-12 month depend time study entry .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Patients one follow indication chronic warfarin anticoagulation ( patient may either new candidate anticoagulation may already receive warfarin ) : 1 . Atrial fibrillation ( paroxysmal , persistent permanent , due reversible cause , document ECG ) atrial flutter . 2 . A prosthetic heart valve aortic mitral position require chronic anticoagulation . 3 . A history venous thromboembolic disease ( DVT and/or PE ) require long term anticoagulation ( &gt; 6 month ) . 4 . A history myocardial infarction cardiomyopathy require anticoagulation . 5 . Currently receive chronic warfarin therapy another indication list , Sponsor approval . 2 . Male female great 18 year age . 3 . Able willing sign IRB approve write informed consent participate study . 4 . Able willing follow instruction , comply protocol requirement , attend require study visit . 1 . Contraindications anticoagulation list warfarin package insert ( Appendix D ) , active bleeding lesion risk bleed gastric ulceration , colonic cerebral AV malformation , cerebral aortic aneurysm , pericarditis endocarditis . Patients recent ( &lt; 14 day screen ) surgery invasive procedure undergo surgery invasive procedure , lumbar puncture . Patients blood dyscrasias inherited disorder hemostasis . Patients history hemorrhagic tendency prior serious hemorrhagic event hemorrhage within cranium , eye , spinal cord , retroperitoneum , gastrointestinal tract . 2 . Laboratory evidence screen clinically significant active bleeding , unexplained positive occult blood stool , unexplained positive urinary blood trace positive hemoglobin . 3 . Concomitant use anticoagulant antiplatelet agent may add hemostatic burden clopidogrel , ticlopidine , heparin low molecular weight heparin ( LMWH ) , regular use non selective long act NSAIDs discontinue prior initiate ATI 5923/warfarin dosing ( daily use 81100 mg aspirin allow ) . 4 . A life expectancy &lt; 1 year , end stage renal failure require dialysis , end stage pulmonary disease require home oxygen , severe heart failure ( NYHA class IV ) . 5 . Dementia , severe psychiatric disorder , ongoing alcohol substance abuse . 6 . Laboratory screen value indicate severe anemia ( Hb &lt; 10 gm/L ) , thrombocytopenia ( platelet count &lt; 90,000/mcL ) , active liver disease . 7 . Patients condition interfere determination INR use INRatio device , i.e. , hematocrit &lt; 30 % &gt; 55 % . Patients antiphospholipid syndrome may abnormal INR result enrol . 8 . History non disable ischemic stroke within last 3 month , prior major disable ischemic stroke , history intracranial bleeding . 9 . Pregnant nursing woman woman childbearing potential use adequate contraception , oral implantable contraceptive , IUD , barrier method ( IUD condom ) spermicide . 10 . Currently participate another clinical trial screening , treatment investigational drug within 30 day first dose study medication , patient previously participate ATI5923 trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>Vitamin K-dependent clot factor inhibitor</keyword>
	<keyword>Coumadin</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Prosthetic heart valve</keyword>
	<keyword>Venous thromboembolic disease</keyword>
	<keyword>Myocardial infarction cardiomyopathy</keyword>
	<keyword>Patients one follow indication chronic warfarin anticoagulation :</keyword>
	<keyword>Atrial fibrillation ( paroxysmal , persistent permanent , due reversible cause , document ECG ) atrial flutter ;</keyword>
	<keyword>A prosthetic heart valve aortic mitral position require chronic anticoagulation ;</keyword>
	<keyword>A history venous thromboembolic disease ( DVT and/or PE ) require long term anticoagulation ( &gt; 6 month ) ;</keyword>
	<keyword>A history myocardial infarction cardiomyopathy require anticoagulation .</keyword>
	<keyword>Currently receive chronic warfarin therapy another indication list , Sponsor approval .</keyword>
</DOC>